Novel tetraphenylene anthracene compounds are disclosed, which can be used as charge transporting materials, emitters, hosts in an organic electroluminescent device. These novel compounds offer better device performance. Also disclosed are an electroluminescent device and a formulation.

An organic compound that emits red light having a long wavelength and that is represented by formula [1] below. In the formula [1], R.sub.1 to R.sub.24 are each independently selected from a hydrogen atom or a substituent. ##STR00001##

Embodiments of prodrugs of PKC modulators that show efficacy coupled with low levels of toxicity and improved stability are provided. The prodrug compounds are useful in academic research (animal studies), as candidates for preclinical research, and as therapeutic agents. By taking advantage of a pharmacophore-based strategy, this design strategy provides access to prodrugs of PKC modulators of diverse scaffolds including tigliane diterpenes, ingenane diterpenes, daphnane diterpene orthoesters, diacylglycerols, and bryostatins, and analogs thereof. In particular, embodiments of the prodrug ingenane esters having substitutions at C20 and their use as therapeutic agents are provided.

According to the present invention, as a monomer which is unlikely to be crystallized in a curable composition for manufacturing an optical member and which enables manufacture of a cured product having a high level of moisture-heat resistance, a compound represented by General Formula (A) is provided. ##STR00001## In the formula, Ar.sup.11 and Ar.sup.12 each independently represent an aryl group or a heteroaryl group; X.sup.1, Y.sup.1, X.sup.2, Y.sup.2, Z.sup.1, and Z.sup.2 each independently represent a nitrogen atom or a carbon atom, or the like; Ar.sup.13 and Ar.sup.14 each independently represent an arylene group or a heteroarylene group, where at least one of Ar.sup.13 or Ar.sup.14 is a group other than a phenylene group; R.sup.3 to R.sup.6 each independently represent a substituent, q and r each independently are an integer of 0 to 4, and v and w each independently are an integer of 0 or more; L.sup.1 and L.sup.2 each independently represent a single bond, an oxygen atom, an ester bond, or the like; R.sup.11 and R.sup.12 each independently represent a divalent linking group containing a branched alkylene group; and R.sup.21 and R.sup.22 each independently represent a hydrogen atom or a methyl group.

The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

An amine-based compound and an organic light-emitting device including the same are provided. The organic light-emitting device may include: a first electrode; a second electrode facing the first electrode; and an organic layer between the first electrode and the second electrode, the organic layer including an emission layer and at least one of the amine-based compound.

Methods and compositions containing a phorbol ester or derivative of a phorbol ester are provided for prevention and treatment of sudden acute respiratory syndrome (SARS) coronavirus infection, including SARS-CoV-2 infection and related COVID-19 disease. Also provided are methods and compositions for preventing and treating acute inflammatory conditions and related pathogenic injuries, including Acute Respiratory Distress Syndrome (ARDS) and cytokine storm syndrome (CSS) seen in severe SARS-CoV-2/COVID-19 cases.

The present invention relates to a method for preparing an organic semiconducting layer comprising the steps: a) providing a first composition in a first vacuum thermal evaporation source, the first composition comprising aa) a first organic compound, the first organic compound comprising at least one unsubstituted or substituted C.sub.10-C.sub.30 condensed aryl group and/or at least one unsubstituted or substituted C.sub.3-C.sub.30 heteroaryl group, wherein the one or more substituent(s) if present, are selected from the group consisting of (i) deuterium, (ii) a halogen, (iii) a C.sub.1 to C.sub.22 silyl group, (iv) a C.sub.1 to C.sub.30 alkyl group, (v) a C.sub.1 to C.sub.10 alkylsilyl group, (vi) a C.sub.6 to C.sub.22 arylsilyl group, (vii) a C.sub.3 to C.sub.30 cycloalkyl group, (viii) a C.sub.2 to C.sub.30 heterocycloalkyl group, (ix) a C.sub.6 to C.sub.30 aryl group, (x) a C.sub.2 to C.sub.30 heteroaryl group, (xi) a C.sub.1 to C.sub.30 perfluoro-hydrocarbyl group, or (xii) a C.sub.1 to C.sub.10 trifluoroalkyl group, wherein the first organic compound has i) a dipole moment in the range of ≥0 and ≤2 Debye; and ii) a molecular weight in the range of ≥400 and ≤1,800; and bb) a metal borate compound; b) transferring the first composition from the solid phase into the gas phase in a vacuum chamber; and c) depositing the first composition on a substrate to form the organic semiconducting layer, a composition for use therein, and an organic electronic device prepared this way.

The present disclosure relates to an organic electroluminescent compound represented by formula 1 and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, an organic electroluminescent device having improved driving voltage, luminous efficiency, and/or lifespan characteristics can be provided.

The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.